Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines
PARIS & OXFORD, England & BOSTON--(BUSINESS WIRE)-- Sanofi
and Exscientia announced today a groundbreaking research collaboration
and license agreement to develop up to 15 novel small molecule
candidates across oncology and immunology, leveraging Exscientia’s
end-to-end AI-driven platform utilising actual patient samples. The
companies have been working together since 2016 and in 2019, Sanofi
in-licensed Exscientia’s novel bispecific small molecule candidate
capable of targeting two distinct targets in inflammation and
immunology.
More info >> |
